Margins Beat, Volume Stuck — The Pricing Rescue
Kajaria delivered a 19.6% EBITDA margin, beating its 18–19% guidance by 70 basis points. But the gain came from pricing power (+11% realization), not volume growth—which stayed at just 6% in Q1. Management's promise of double-digit volume growth over the next nine months remains unproven.
₹1,328 Cr
+20.4% YoY; 6% volume + 11% pricing + mix
19.6%
Beat 18–19% guidance by 70 bps; +390 bps YoY
₹171 Cr
+55% YoY; margin expansion dominates
6%
Q1 FY27; April soft, May–July recovery claimed
The margin beat—what drove it
Kajaria's 19.6% EBITDA margin reads as a beat on first glance, and technically it is—the guidance range was 18–19%. But the route to that margin tells a different story: revenue grew 20.4% YoY, yet organic volume growth was just 6%. The gap was made up by pricing. Realization (price per unit) rose 11%, a direct consequence of gas cost pass-through. In Q1, gas prices in the Morbi cluster spiked from ₹48/SCM to ₹85–88/SCM post-conflict, forcing competitors to raise prices 40–45%. Kajaria's North and South plants, fed by more stable GAIL and CGD supply, only needed 10–11% increases. The net result: Kajaria's price gap versus Morbi narrowed from 40% to 20%, a genuine competitive gain. But the margin expansion itself is a pricing story, not a volume growth story—a critical distinction for sustainability.
Gas market is very volatile with the war still on. One day, there is no war. Second day, the war is on. And the situation is very, very volatile.
What changed on this call
6% volume growth plus 11% pricing = 20% revenue growth—evidence of pricing power in volatile gas market
Confirmed: ₹1,328 Cr revenue (+20.4% YoY). Breakdown: April soft (Morbi shutdown, labor shortage), May–July recovery. Pricing 10–13% region-wise, validated by gas cost spike (Morbi ₹48→₹85/SCM).
Supported
EBITDA margin 19.6% shows strong execution; guidance range 18–19% already exceeded in Q1
Delivered 19.6% OPM vs 16.72% prior year (390 bps expansion). Guidance range already beaten. But expansion is pricing-driven, not organic volume-driven.
Supported (with caveat)
Price gap vs Morbi narrowed from 40% to 20%, validating market share gains and multi-location manufacturing edge
Morbi GSPC-dependent gas spiked 48→86/SCM. Kajaria's GAIL/CGD plants only needed 10–11% increases vs Morbi's 40–45%. Gap compression credible and structural.
Supported
Double-digit volume growth promised for next 9 months (April onward); driven by dealer network and project pipeline ('two very big builders')
Q1 volume was 6%; April was soft (specific reasons: Morbi shutdown, labor shortage, dealer pre-lifting). May–July recovery cited but no specific volume numbers given. Project deals 'very big' but unsigned/unquantified.
Partial / unproven
₹1,000 Cr+ EBITDA FY27 target is achievable on current trajectory
Q1 EBITDA: ₹260 Cr (19.6% margin on ₹1,328 Cr revenue). Annualized run-rate: ~₹1,040 Cr. Credible if margins hold and volume accelerates; contingent on gas stability and volume delivery.
Supported (conditional)
Four things that changed vs. prior quarters
1. Volume guidance was formalized. Prior Q4 FY26 call: no numeric volume target. Now: management explicitly promised double-digit volume growth for the next 9 months (April–December), implying a sustained run-rate of 10%+ vs ₹118 million sqm (FY26 baseline). This is new accountability.
2. Capex intensity escalated with concrete project names. Prior: vague 'brownfield expansion.' Now: ₹375 Cr announced for two specific plants—Srikalahasti (South, ₹210 Cr for 10 MSM) and Gailpur (North, ₹165 Cr for 11 MSM)—commissioning Q1 FY28. Higher capex-to-capacity ratio (₹165 Cr for 11 MSM vs prior ₹150–160 Cr for 5–6 MSM) justified by newer kiln technology and lower opex.
3. Market share strategy pivoted from retail to projects. Prior: disruptions from Morbi (unspecified). Now: price competitiveness restored, distribution network (1,800 dealers) strengthened, and a new 'project' lever identified—institutional/builder sales that are incremental to retail.
4. Bathware margins were reset candidly. Prior (Q4 FY26): Kerovit scaling strongly. Now: management candid that FY27 is a 'tough year' for Bathware due to restructuring and new CBO (hired April). Expects margin recovery in FY28. This is a realistic retreat, not a surprise.
The bull-bear ledger
EBITDA margin beat: 19.6% vs 18–19% guidance
PAT growth +55% YoY validates margin expansion and cost discipline
Price gap vs Morbi narrowed from 40% to 20%—genuine structural competitive gain
Multi-location manufacturing (3 Morbi, 3 North, 2 South) insulates from regional gas shocks
Capex technology claim: 11 MSM for ₹165 Cr vs prior 5–6 MSM for ₹150–160 Cr—2x turnover efficiency
Adhesives +80% YoY—secular tailwind as price gap vs unorganized narrows
Q1 volume growth only 6%; margin expansion driven by pricing (+11%), not organic growth
Double-digit volume growth promised for 9M is unproven; contingent on May–July momentum (unquantified) and unsigned project deals
Bathware ('tough year') drags blended profitability; ₹122 Cr revenue growing fast but margins under pressure during restructuring
Outsourcing rising from 30% to 40% FY27 to absorb volume growth; lower-margin outsourced tiles will dilute blended profitability near-term
Capex ₹375 Cr back-loaded to FY28; FY27 will rely on outsourcing and existing capacity. ROI timing uncertain
April softness (Morbi shutdown, labor shortage) specific to Q1, but if macro cools, volume weakness may persist
Risks ranked by how much they should concern a holder
Gas price volatility (ongoing geopolitical risk)
HighMorbi cluster already spiked 48→88/SCM; pricing pass-through (11% achieved in Q1) has limits. If gas sustains or escalates, Kajaria's cost base rises and pricing ceiling compresses. Margin erosion risk if pass-through fails.
Volume growth unproven at scale; project pipeline unsigned
HighQ1 was 6% volume; double-digit for 9M is promised but lacks binding orders. Management cites 'two very big builders' but no contracts disclosed. If project deals stall or May–July momentum fades, ₹1,000 Cr EBITDA target and guidance miss.
Capex execution and ROI slippage
Medium₹375 Cr capex (Srikalahasti, Gailpur) spills into FY28. If commissioning is delayed or volumes don't absorb new capacity, ROI and margins suffer. Outsourcing dependency (40% FY27) is a tactical workaround, not a scaling solution.
Bathware margin deterioration during restructuring
MediumKerovit ₹122 Cr (+33%) but margins 'tough' FY27. New CBO and 100% ownership (Aravali stake acquired) should help, but execution risk during integration. Blended company guidance (18–19%) relies on tiles carrying Bathware drag.
April softness recurrence if macro cools
MediumQ1 softness attributed to Morbi shutdown, labor shortage, dealer pre-lifting—specific, transient causes. But if RBI tightening or construction slowdown hits demand, volume growth stalls and forward guidance falters.
Earnings quality: pricing-driven, not organic growth
Low-MediumPAT +55% looks strong, but decomposition shows it's margin expansion on existing volume + pricing tailwind. If gas reverts, pricing withers. Organic volume growth (6% Q1) is the true bellwether; it's weak.
How the market is positioned
The price action: Kajaria announced results on Friday, July 31. The stock popped +1.37% on day 1 (delivery 56.4%, suggesting conviction), but the move faded—by day 3 it was -1.01%, and by day 5 it had fallen to -2.59% from the post-result spike. That fade is telling: the market initially liked the margin beat, then repriced negative on realization that volume growth is weak and future delivery hinges on unproven catalysts (project wins, capex ramp). As of August 18, the stock is at ₹1,225.8, having recovered from the day-5 trough. It now sits 3.86% below its all-time high of ₹1,275 but 40.96% above its 52-week low of ₹869.6. It trades above its 200-, 50-, and 20-day moving averages, a bullish chart position. However, RSI at 53.7 is neutral—no overbought signal, no sustained momentum.
FII and DII flows: Foreign investors hold 11.58% in Q1 FY27 (up 1.35 percentage points from Q4 FY26's 10.23%), a net add. Domestic institutions hold 26.25% (down 1.23 percentage points from 27.48% prior quarter), a slight trim. Promoters remain steady at 47.69%. On the surface, FII are adding and DII slightly trimming—a mixed signal. But zoom out: FII ownership has declined from 15.79% in FY25 Q1 to 11.58% now—a multi-quarter exit. DII similarly slipped from 27.39% to 26.25% over the same period. Institutions are cautious; the Q1 beat hasn't reversed the longer-term trimming trend.
What it means: The stock's price action (pop-and-fade) and institutional trim aligns with the fundamental read—Kajaria has delivered steady margin execution and cost discipline, but forward growth depends on unproven volume acceleration. The market is waiting for evidence.
The debate
1 · Q2–Q3 volume growth trajectory (next 6 months)
Management claimed May–July recovery (post-April softness). Q2 results will either validate or undermine the 'double-digit for 9M' promise. If Q2–Q3 volume comes in at 8%+ YoY sustained, the bull case gains legs. If it drops back to 4–6%, the guidance is in jeopardy.
2 · Project pipeline conversion and order flow (Q3–Q4 FY27)
Management's 'two very big builders' breakthrough is a lynchpin. By Q3, we should see early signs of order intake or dealer reports of new institutional offtake. Unsigned deals are a red flag; signed contracts or ramp signals are the validation.
3 · Capex plant commissioning and utilization (Q4 FY27–Q1 FY28)
Srikalahasti (10 MSM, ₹210 Cr) and Gailpur (11 MSM, ₹165 Cr) are due Q1 FY28. The ramp schedule, initial output, and margin accretion (management's 2x turnover claim) will be critical. Delays or underutilization are margin-negative. On-time, full-utilization ramp de-risks the capex thesis.
The single number to track from here
It's not the headline EBITDA margin (already beaten guidance). It's organic volume growth. Q1 was 6%, and management has promised double-digit for the next 9 months. If Q2–Q3 comes in at 8%+, the thesis works. If it drops to 5–6%, forward guidance misses and the stock reprices. Everything else—pricing power, capex ROI, project wins—cascades from volume. That's the bellwether.
Kajaria Ceramics delivered on margin guidance and showed genuine operational discipline in a volatile gas-price environment. The 19.6% EBITDA beat and 55% PAT growth are real achievements. But the quarter was margin-driven by pricing, not volume-driven, and the company's forward promise—double-digit volume growth, ₹1,000 Cr EBITDA, capex ROI—rests on unproven catalysts: project pipeline conversions, continued sales acceleration, and two plants that won't generate meaningful earnings uplift until late FY28. The stock's price action (pop and fade) reflects this uncertainty. The market is waiting for evidence. Verdict: Hold. Kajaria is a solidly-run ceramics franchise with a structural edge from the Morbi disruption and multi-location manufacturing resilience. But near-term upside depends on volume proving out at scale. The risk/reward is balanced. Add on a sustained 10%+ volume reacceleration (Q2–Q3 delivery); trim on volume stall or gas reversion.
Informational and educational content only. Not investment advice.